One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars ...

The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new agency officials ...

“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — ...

AstraZeneca announced that it will invest $50 billion in the U.S. by 2030, including a multi-billion-dollar manufacturing ...

CASP, the protein structure prediction contest that launched DeepMind’s Alphafold to international fame and a Nobel Prize, ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

University of Minnesota president Rebecca Cunningham is drawing on her experience as an emergency physician in this ...